Article
Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Expert review of molecular diagnostics - 1 Mar 2017
Malapelle Umberto, Sirera Rafael, Jantus-Lewintre Eloísa, Reclusa Pablo, Calabuig-Fariñas Silvia, Blasco Ana, Pisapia Pasquale, Rolfo Christian, Camps Carlos
Abstract excerpt
INTRODUCTION: The discovery of driver mutations in non-small cell lung cancer (NSCLC) has led to the development of genome-based personalized medicine. Fifteen to 20% of adenocarcinomas harbor an epidermal growth factor receptor (EGFR) activating mutation associated with responses to EGFR tyrosine kinase inhibitors (TKIs). Individual laboratories' expertise and the availability of appropriate equipment are...
Topics
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- ErbB Receptors
- Humans
- Lung Neoplasms
- Mutation
- Reagent Kits, Diagnostic
- Real-Time Polymerase Chain Reaction
- Reverse Transcriptase Polymerase Chain Reaction